Corbus数据公布后股价暴涨,截止发帖时间已经上涨3倍多。
近日,石药集团/Corbus在2024年(ASCO-GU2024)上,公布了靶向nectin-4抗体药物偶联物(ADC)SYS6002的I期剂量递增数据。
具体数据可以查询Corbus发布的公告...查看全文
Corbus(CRBP)01-26 20:55
$Corbus制药控股(CRBP)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0000950170-24-007703 Act: 34 Size: 28 MB 网页链接查看全文
Corbus(CRBP)02-05 21:15
$Corbus制药控股(CRBP)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0000950170-24-011013 Act: 34 Size: 29 MB 网页链接查看全文
Corbus(CRBP)02-06 05:55
$Corbus制药控股(CRBP)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0000929638-24-000374 Act: 34 Size: 110 KB 网页链接查看全文
Corbus(CRBP)01-27 05:35
$Corbus制药控股(CRBP)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001214659-24-001240 Act: 34 Size: 84 KB 网页链接查看全文
Corbus(CRBP)01-31 05:25
$Corbus制药控股(CRBP)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000929638-24-000303 Size: 7 KB 网页链接查看全文
Corbus(CRBP)02-29 06:05
$Corbus制药控股(CRBP)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001273087-24-000053 Act: 34 Size: 81 KB 网页链接查看全文
Corbus(CRBP)03-01 06:15
$Corbus制药控股(CRBP)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-24-004119 Size: 6 KB 网页链接查看全文
Corbus(CRBP)03-21 05:15
$Corbus制药控股(CRBP)$ 8-K Current report, item 8.01 Accession Number: 0000950170-24-034271 Act: 34 Size: 148 KB 网页链接查看全文
股界一粒沙01-27 02:24
$Corbus制药控股(CRBP)$ $新诺威(SZ300765)$ $石药集团(01093)$
Corbus数据公布后股价暴涨,截止发帖时间已经上涨3倍多。
近日,石药集团/Corbus在2024年(ASCO-GU2024)上,公布了靶向nectin-4抗体药物偶联物(ADC)SYS6002的I期剂量递增数据。
具体数据可以查询Corbus发布的公告...查看全文
牛唐2023-03-17 17:31
医药板块速评(2023.03.16)
1、大盘反弹,是继续看多,还是做空良机?
2、$Corbus制药控股(CRBP)、$Elevation Oncology(ELEV)三天翻倍,背后逻辑是什么,谁有潜力成为下一个?
3、$中概互联网指数ETF-KraneShares(KWEB)、$英特尔(INTC)$ 、$台积电(TSM)期权大量成交,后续走势如何看...查看全文
chuminhua2021-06-27 22:45
6月25日,对于Corbus制药公司和自身免疫性疾病治疗药物lenabasum来说,情况并不乐观。
Corbus公司披露了这种合成口服大麻素2型激动剂的一长串失败案例,这次是在罕见的自身免疫性疾病皮肌炎的后期试验中。
早在9月,Corbus公司透露,lenabasum在皮肤系统性硬化症的3期试验中失败,另一项中...查看全文
andrewmed2021-04-21 09:22
文章来源:“凯莱英药闻”微信公众号
4月20日,瑞士创新药企业Synendos Therapeutics宣布延长A轮融资,新加入投资方Ysios Capital,将融资规模扩大至2400万瑞郎。Synendos于2020年11月开启A轮融资,由Kurma Partners和Sunstone Life Science Ventures共同投资,规模为2000万瑞郎。
该笔融...查看全文
$Corbus Pharmaceuticals Holdings, Inc.(CRBP)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2018-02-14 AccNo: 0000905718-18-000208 Size: 39 KB 网页链接
$Corbus Pharmaceuticals Holdings, Inc.(CRBP)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2018-02-01 AccNo: 0000215457-18-004571 Size: 13 KB 网页链接
$Corbus Pharmaceuticals Holdings, Inc.(CRBP)$ 8-K - Current report Filed: 2018-01-30 AccNo: 0001493152-18-001233 Size: 45 KBItem 1.01: Entry into a Material Definitive AgreementItem 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Ar...
$Corbus Pharmaceuticals Holdings, Inc.(CRBP)$ EFFECT - Notice of Effectiveness Filed: 2018-01-17 AccNo: 9999999995-18-000145 Size: 1 KB 网页链接
$Corbus Pharmaceuticals Holdings, Inc.(CRBP)$ 424B3 - Prospectus [Rule 424(b)(3)] Filed: 2018-01-17 AccNo: 0001493152-18-000668 Size: 458 KB 网页链接
$Corbus Pharmaceuticals Holdings, Inc.(CRBP)$ 8-K - Current report Filed: 2018-01-08 AccNo: 0001493152-18-000283 Size: 11 MBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Corbus Pharmaceuticals Holdings, Inc.(CRBP)$ 8-K - Current report Filed: 2018-01-05 AccNo: 0001493152-18-000241 Size: 36 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接
$Corbus Pharmaceuticals Holdings, Inc.(CRBP)$ 8-K - Current report Filed: 2018-01-05 AccNo: 0001493152-18-000241 Size: 36 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接
$Corbus Pharmaceuticals Holdings, Inc.(CRBP)$ S-3 - Registration statement under Securities Act of 1933 Filed: 2018-01-05 AccNo: 0001493152-18-000239 Size: 2 MB 网页链接
$Corbus Pharmaceuticals Holdings, Inc.(CRBP)$ S-3 - Registration statement under Securities Act of 1933 Filed: 2018-01-05 AccNo: 0001493152-18-000239 Size: 2 MB 网页链接